Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Eos Angel Investment Syndicate
Deal Size : $4.8 million
Deal Type : Financing
Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round
Details : The financing will be used in the development for ILC’s lead hybrid interferon drug, Alfacyte (human alpha interferon), an anti-viral medicine for the treatment of upper respiratory tract viral infections, including SARS-CoV-2 which causes Covid-19.
Product Name : Alfacyte
Product Type : Protein
Upfront Cash : Undisclosed
April 26, 2023
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Eos Angel Investment Syndicate
Deal Size : $4.8 million
Deal Type : Financing
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ILC Therapeutics Announces ‘Significant’ COVID-19 Drug Breakthrough
Details : ILC Therapeutics' unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 in cell culture than other commercially-available Interferons such as Interferon alpha 2 and Interferon beta...
Product Name : Alfacyte
Product Type : Protein
Upfront Cash : Inapplicable
July 10, 2020
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ILC Seeks £4m to Help Advance COVID-19 Trials
Details : The company has patented a new Interferon-Alpha subtype called Interferon Alpha 14 which can be given to patients through injection or inhalation.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
April 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable